SSc phenotype | Patients with SSc, n=74 |
Age, median (IQR) | 57 (49, 63) |
Female | 63 (85) |
Disease subtype | |
lcSSc | 50 (68) |
dcSSc | 24 (32) |
Disease duration (years), median (IQR) | 8 (2, 16) |
History of | |
Digital ulceration | 16 (22) |
Calcinosis | 17 (23) |
Myositis | 3 (4) |
GORD | 66 (90) |
Interstitial lung disease | 29 (39) |
Current use of DMARD | 42 (57) |
Clinical profile | |
Total modified Rodnan skin score, median (IQR) | 2 (1, 6) |
Digital ulceration | 10 (14) |
Tendon friction rubs | 2 (3) |
Calcinosis | 14 (19) |
Antibody profile | |
ANA | 69 (93) |
ACA | 27 (36) |
Scl70 | 22 (30) |
CV risk factors | |
Any CV risk factors, | 21 (28) |
FHx premature CVD | 8 (11) |
Smoking | 6 (8) |
Dyslipidaemia | 3 (4) |
HBP | 8 (11) |
One CV risk factor | 16 (21) |
Two CV risk factors | 5 (7) |
N % presented unless stated otherwise.
ACA, anti-centromere antibody; ANA, antinuclear antibodies; CV, cardiovascular; CVD, cardiovascular disease; dcSSc, diffuse cutaneous systemic sclerosis; DMARD, disease modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; FHx, family history; GORD, gastro-oesophageal reflux disease; HBP, high blood pressure; lcSSc, limited cutaneous systemic sclerosis; Scl70, anti-topoisomerase antibody; SSc, systemic sclerosis.